AveXis reports new data continuing to show significant therapeutic benefit of Zolgensma®
AveXis, a Novartis company, announced that new interim data from the Phase 3 SPR1NT trial in pre-symptomatic patients as well as interim data from the ongoing Phase 3 STR1VE clinical program for Zolgensma® (onasemnogene abeparvovec-xioi) showed positive outcomes in patients with SMA Type 1. September 19, 2019